Sökning: onr:"swepub:oai:DiVA.org:uu-278901" > World Federation of...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03159naa a2200385 4500 | |
001 | oai:DiVA.org:uu-278901 | |
003 | SwePub | |
008 | 160226s2013 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2789012 URI |
024 | 7 | a https://doi.org/10.3109/15622975.2012.7397082 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hasan, Alkomiet4 aut |
245 | 1 0 | a World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2 :b update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects |
264 | c 2012-12-06 | |
264 | 1 | b Informa UK Limited,c 2013 |
338 | a print2 rdacarrier | |
520 | a These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Psykiatri0 (SwePub)302152 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Psychiatry0 (SwePub)302152 hsv//eng |
700 | 1 | a Falkai, Peter4 aut |
700 | 1 | a Wobrock, Thomas4 aut |
700 | 1 | a Lieberman, Jeffrey4 aut |
700 | 1 | a Glenthoj, Birte4 aut |
700 | 1 | a Gattaz, Wagner F4 aut |
700 | 1 | a Thibaut, Florence4 aut |
700 | 1 | a Möller, Hans-Jürgen4 aut |
700 | 1 | a von Knorring, Larsu Uppsala universitet,Psykiatri, Akademiska sjukhuset4 ctb0 (Swepub:uu)larsvon |
710 | 2 | a Uppsala universitetb Psykiatri, Akademiska sjukhuset4 org |
773 | 0 | t World Journal of Biological Psychiatryd : Informa UK Limitedg 14:1, s. 2-44q 14:1<2-44x 1562-2975x 1814-1412 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-278901 |
856 | 4 8 | u https://doi.org/10.3109/15622975.2012.739708 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy